Table 1 The characteristics of patients according to serum hs-CRP/PAB ratio level.

From: High sensitivity C-reactive protein to prealbumin ratio measurement as a marker of the prognosis in acute coronary syndrome

Characteristics Low hs-CRP/PAB group High hs-CRP/PAB group P value
n = 329 n = 330
Age (year) 65.16 ± 10.37 67.80 ± 11.77 0.002
Male gender, n (%) 191 (58.1) 169 (51.2) 0.078
Current smoker, n (%) 89 (27.05) 100 (30.30) 0.356
Hypertension, n (%) 196 (59.57) 217 (65.76) 0.101
Diabetes mellitus, n (%) 78 (23.71) 102 (30.90) 0.038
Previous CAD, n (%) 36 (10.94) 59 (17.88) 0.011
Killip class II-IV, n (%) 18 (5.47) 31 (9.39) 0.055
Heart rate (bpm) 72 (14.00) 76 (22.25) <0.001
Laboratory measurement
   Hemoglobin (g/dL) 13.60 ± 1.64 12.82 ± 1.77 <0.001
   Platelet (×103/μL) 224.63 ± 55.63 226.02 ± 70.17 0.778
   Leukocyte (×103/μL) 6.21 (1.91) 7.01 (3.35) <0.001
   Glucose (mg/dL) 95.84 (26.93) 108.18 (49.14) <0.001
   eGFR (mL/min/1.73 m2) 84.48 ± 27.60 82.40 ± 32.44 0.010
   PAB (mg/dL) 19.84 ± 3.64 15.73 ± 4.39 <0.001
   Hs-CRP/PAB ratio 0.004 (0.003) 0.054 (0.101) <0.001
   GOT (u/L) 21.00 (10.00) 24.00 (20.00) <0.001
   GPT (u/L) 19.00 (13.00) 21.00 (19.00) 0.010
   LDL-cholesterol (mg/dL) 101.87 ± 34.75 101.92 ± 32.69 0.984
   Hs-CRP (mg/dL) 0.08 (0.06) 0.78 (1.40) <0.001
Angiography, n (%) 169 (51.37) 164 (49.70) 0.668
   1 vessel disease 110 (33.43) 85 (25.76)  
   2 vessel diseases 49 (14.89) 45 (13.64)  
   3 vessel diseases 10 (3.04) 34 (10.30) <0.001
Treatment, n (%)
   Primary PCI 12 (3.65) 17 (5.15) 0.347
   LMWH 100 (30.40) 116 (35.15) 0.193
   Anti-platelet 321 (97.57) 323 (97.88) 0.789
   Beta-blocker 207 (62.92) 195 (59.09) 0.191
   ACEI/ARB 140 (42.55) 169 (51.21) 0.026
   Statin 156 (47.42) 148 (44.85) 0.508
  1. Abbreviation: Hs-CRP: high sensitivity C-reactive protein; PAB: prealbumin; CAD: coronary artery disease; eGFR: estimated glomerular filtration rate; GOT: glutamate oxaloacetate transaminase; GPT: glutamate pyruvate transaminase; LDL: low density lipoproteins; PCI: percutaneous coronary intervention; LMWH: low molecular weight heparin; ACEI: angiotensin-converting-enzyme inhibitor; ARB: angiotensin receptor blockers.